Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Low Bone Density in Cystic Fibrosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 2-30 years~* clinically stable condition~* regular menses in females~* low Bone Mineral Apparent Density for age (defined as BMAD Z-score ≤-2.0 if age ≤18 years or ≤-2.5 if age \>18 years).~Exclusion Criteria:~* two or more episodes of hypercalcemia and/or hypercalciuria~* contraindications to 25-OH vitamin D or alendronate treatment~* recent transplantation~* other diseases or medications (glucocorticoids excepted) associated with bone loss.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Alendronate (Type: ACTIVE_COMPARATOR): 128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~65 subjects were randomized to this arm. Oral alendronate dose: 5 mg/day, if body weight ≤25 kg; 10 mg/day, if body weight \>25 kg.
- Placebo (Type: PLACEBO_COMPARATOR): 128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~63 subjects were randomized to this arm. Oral placebo (inactive pills).

Based on this trial design, predict the completion outcome and termination type (if applicable).